 Ian Purvis
Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Otx Transcription Factors | 1 | 2026 | 15 | 0.950 |
Why?
| | Gene Regulatory Networks | 1 | 2026 | 318 | 0.790 |
Why?
| | Retina | 1 | 2026 | 324 | 0.780 |
Why?
| | Cerebellar Neoplasms | 2 | 2023 | 177 | 0.720 |
Why?
| | Medulloblastoma | 2 | 2023 | 215 | 0.710 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2026 | 905 | 0.660 |
Why?
| | B7 Antigens | 1 | 2020 | 18 | 0.650 |
Why?
| | Exosomes | 1 | 2020 | 104 | 0.600 |
Why?
| | Carcinogenesis | 1 | 2020 | 229 | 0.560 |
Why?
| | Linkage Disequilibrium | 6 | 2004 | 246 | 0.410 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2004 | 2145 | 0.300 |
Why?
| | Enhancer Elements, Genetic | 1 | 2026 | 192 | 0.210 |
Why?
| | CRISPR-Cas Systems | 1 | 2026 | 170 | 0.210 |
Why?
| | Pharmacogenetics | 1 | 2004 | 172 | 0.180 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2002 | 9 | 0.180 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2002 | 43 | 0.180 |
Why?
| | X Chromosome | 1 | 2001 | 67 | 0.180 |
Why?
| | Receptor, Insulin | 1 | 2001 | 94 | 0.170 |
Why?
| | Haplotypes | 2 | 2002 | 490 | 0.170 |
Why?
| | Psoriasis | 1 | 2002 | 112 | 0.160 |
Why?
| | Membrane Transport Proteins | 1 | 2002 | 154 | 0.160 |
Why?
| | Migraine Disorders | 1 | 2001 | 112 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 3 | 2004 | 2363 | 0.150 |
Why?
| | Alleles | 1 | 2001 | 879 | 0.140 |
Why?
| | Computational Biology | 1 | 2001 | 680 | 0.120 |
Why?
| | Chromosome Mapping | 3 | 2002 | 510 | 0.120 |
Why?
| | ortho-Aminobenzoates | 2 | 2004 | 10 | 0.100 |
Why?
| | Glucuronosyltransferase | 2 | 2004 | 18 | 0.100 |
Why?
| | Glioblastoma | 1 | 2017 | 353 | 0.100 |
Why?
| | Cell Cycle Proteins | 1 | 2017 | 628 | 0.100 |
Why?
| | DNA Methylation | 1 | 2017 | 681 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1455 | 0.080 |
Why?
| | DNA Primers | 2 | 2001 | 512 | 0.080 |
Why?
| | Base Sequence | 3 | 2002 | 2190 | 0.080 |
Why?
| | Mice | 1 | 2026 | 18339 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1318 | 0.070 |
Why?
| | Gene Frequency | 3 | 2004 | 481 | 0.060 |
Why?
| | Gilbert Disease | 1 | 2004 | 1 | 0.050 |
Why?
| | Hyperbilirubinemia | 1 | 2004 | 11 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2004 | 117 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2001 | 3409 | 0.050 |
Why?
| | Animals | 1 | 2026 | 38058 | 0.050 |
Why?
| | Protein Binding | 2 | 2017 | 2273 | 0.050 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 56 | 0.050 |
Why?
| | Genotype | 3 | 2004 | 1833 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2023 | 2496 | 0.050 |
Why?
| | Humans | 11 | 2023 | 144759 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2023 | 3540 | 0.050 |
Why?
| | Transcription Factors | 2 | 2023 | 1741 | 0.050 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2001 | 8 | 0.050 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2001 | 20 | 0.040 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2001 | 26 | 0.040 |
Why?
| | San Francisco | 1 | 2001 | 60 | 0.040 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2002 | 32 | 0.040 |
Why?
| | North Carolina | 1 | 2001 | 128 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2155 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2930 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2002 | 170 | 0.040 |
Why?
| | Genome, Human | 1 | 2002 | 422 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2001 | 1054 | 0.040 |
Why?
| | DNA | 2 | 2004 | 1463 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 1998 | 128 | 0.030 |
Why?
| | Cytomegalovirus | 1 | 1998 | 168 | 0.030 |
Why?
| | Butyric Acid | 1 | 2017 | 6 | 0.030 |
Why?
| | CpG Islands | 1 | 2017 | 165 | 0.030 |
Why?
| | Gene Silencing | 1 | 2017 | 205 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 596 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2001 | 3604 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1257 | 0.020 |
Why?
| | Male | 3 | 2002 | 72315 | 0.020 |
Why?
| | Polymorphism, Genetic | 2 | 2004 | 612 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1821 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2430 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2004 | 64 | 0.010 |
Why?
| | Dinucleotide Repeats | 1 | 2004 | 6 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 143 | 0.010 |
Why?
| | Female | 2 | 2002 | 78271 | 0.010 |
Why?
| | Isoenzymes | 1 | 2004 | 299 | 0.010 |
Why?
| | Chromosomes | 1 | 2002 | 108 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2004 | 824 | 0.010 |
Why?
| | Genetic Markers | 1 | 2002 | 331 | 0.010 |
Why?
| | Amino Acid Chloromethyl Ketones | 1 | 1998 | 24 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2004 | 2029 | 0.010 |
Why?
| | Trypsin | 1 | 1998 | 76 | 0.010 |
Why?
| | beta-Lactams | 1 | 1998 | 32 | 0.010 |
Why?
| | Genetic Variation | 1 | 2004 | 983 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1998 | 102 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1998 | 381 | 0.010 |
Why?
| | Catalytic Domain | 1 | 1998 | 232 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 540 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 1998 | 454 | 0.010 |
Why?
| | DNA, Viral | 1 | 1998 | 358 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 1998 | 750 | 0.010 |
Why?
| | Saccharomyces cerevisiae | 1 | 1998 | 579 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3162 | 0.010 |
Why?
| | Prospective Studies | 1 | 2004 | 7990 | 0.010 |
Why?
|
|
Purvis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|